Form 4: Pharvaris Executive Sells Shares Under 10b5-1 Plan

Pharvaris N.V. reports that Chief Early Development Officer Anne Lesage executed a series of stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Summary

• Anne Lesage, Chief Early Development Officer at Pharvaris N.V., engaged in multiple transactions involving the exercise of stock options and subsequent sale of common stock.
• These transactions occurred on June 29 and June 30, 2026, and were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled.
• The exercises involved options with strike prices of $2.59 and $8.05, and the sales were executed at weighted average prices ranging from $35.00 to $35.86.
• Following these transactions, Lesage's beneficial ownership of common stock has been adjusted, with some holdings now reported as indirect through GrayMatters Consulting BVBA.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves significant stock sales by an executive, the transactions were conducted under a pre-arranged 10b5-1 plan, mitigating concerns about insider trading and suggesting a planned divestment rather than a reaction to negative company news.

Positives

• Transactions were executed under a Rule 10b5-1 trading plan, which is designed to provide an affirmative defense against allegations of insider trading by establishing a pre-arranged plan for stock transactions.
• The exercise of stock options and subsequent sale of shares at prices significantly higher than the exercise prices ($35.00-$35.86 vs. $2.59-$8.05) indicates a positive return on those options.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market, although conducted under a pre-planned strategy.
• The filing details multiple sales, totaling thousands of shares, which reduces the executive's direct stake in the company.

Risks

• While conducted under a 10b5-1 plan, significant sales by an executive could still lead to negative market perception or be interpreted as a lack of confidence, despite the pre-planned nature.
• The explanation notes that the reporting person undertakes to provide full information regarding shares sold at each separate price upon request, implying complexity in the sales that could lead to scrutiny.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan.
• The sales prices for the transactions ranged from $35.00 to $35.30 (for one set of transactions).
• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of Rule 10b5-1 plans by executives is common practice to manage stock sales in a way that mitigates insider trading concerns, especially for companies in dynamic sectors like biotechnology where stock prices can be volatile.

Stakeholder Impact

• Shareholders: May interpret the executive's sales as a reduction in insider confidence, though the 10b5-1 plan provides a mitigating context.
• Employees: May observe executive compensation strategies and stock divestment patterns.
• Creditors: Unlikely to be directly impacted by this type of transaction.

Next Steps

• The reporting person will continue to hold any remaining beneficial ownership of Pharvaris N.V. common stock.
• The company may receive requests for further information regarding the specific sale prices from the SEC or security holders.

Key Dates

Keywords

Form 4, SEC Filing, Pharvaris N.V., PHVS, Anne Lesage, Stock Options, Insider Trading, 10b5-1 Plan, Beneficial Ownership, Common Stock, Securities Transaction